Holen Sie sich die Stockscreener-App
1.71
2.29%
-0.04
Handel nachbörslich:
1.71
Schlusskurs vom Vortag:
$1.75
Offen:
$1.7752
24-Stunden-Volumen:
15,001
Relative Volume:
0.41
Marktkapitalisierung:
$23.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.59M
KGV:
-1.5833
EPS:
-1.08
Netto-Cashflow:
$-19.79M
1W Leistung:
-11.86%
1M Leistung:
+12.50%
6M Leistung:
-50.43%
1J Leistung:
-68.22%
1-Tages-Spanne:
$1.6598
$1.7752
1-Wochen-Bereich:
$1.6598
$2.04
52-Wochen-Spanne:
$1.43
$6.0199
Calcimedica Inc Stock (CALC) Company Profile
Firmenname
Calcimedica Inc
Sektor
Branche
Telefon
858-952-5500
Adresse
505 COAST BOULEVARD SOUTH, LA JOLLA
Vergleichen Sie CALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
1.71 | 27.11M | 0 | -13.59M | -19.79M | -1.08 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Calcimedica Inc Aktie (CALC) Neueste Nachrichten
HC Wainwright Reiterates “Buy” Rating for CalciMedica (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Receives Reiteration of Buy Rating with $16 P - GuruFocus
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - Citizen Tribune
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Monday - Defense World
CalciMedica Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Stake in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
Bristol-Myers Squibb (NYSE:BMY) vs. CalciMedica (NASDAQ:CALC) Critical Review - Defense World
CalciMedica (NASDAQ:CALC) Shares Up 0.7% – Here’s Why - Defense World
CalciMedica's Breakthrough Research Takes Center Stage at Two Elite Medical Conferences - Stock Titan
CalciMedica Announces Presentations at Upcoming Medical Meetings - PR Newswire
Analysts Offer Predictions for CalciMedica Q4 Earnings - Defense World
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright - Defense World
Corient Private Wealth LLC Acquires Shares of 38,000 CalciMedica, Inc. (NASDAQ:CALC) - The AM Reporter
Graybug Vision stock hits 52-week low at $1.81 - Investing.com India
Graybug Vision stock hits 52-week low at $1.81 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $16 target on CalciMedica stock - Investing.com Australia
CalciMedica’s Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating - TipRanks
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference - PR Newswire
CalciMedica says cash sufficient to fund operating plan into mid-2026 - TipRanks
CALCIMEDICA Earnings Results: $CALC Reports Quarterly Earnings - Nasdaq
CalciMedica Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates - Citizen Tribune
Calcimedica Reports 2024 Financial Results And Provides Clinical & Corporate Updates - MarketScreener
CalciMedica (CALC) to Release Earnings on Thursday - The AM Reporter
CalciMedica Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Atria Investments Inc Buys 7,509 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Thursday - Defense World
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Latham & Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
Finanzdaten der Calcimedica Inc-Aktie (CALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):